Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
insight
/
details

Cell-Free DNA (cfDNA) as a Potential Biomarker for Preeclampsia: Insights and Implications

NextEdge Admin

29 Feb 2024

3 min 37 sec

Cell-free DNA (cfDNA) has recently garnered attention as a potential biomarker for various medical conditions, with a particular focus on its application in the context of preeclampsia. Preeclampsia, a pregnancy-related disorder characterized by elevated blood pressure and organ damage, poses significant risks to both maternal and fetal health, especially when not promptly addressed.

One avenue of investigation revolves around the placental origin of cfDNA. During pregnancy, the placenta releases small fragments of DNA into the maternal bloodstream. These fragments, identified as cfDNA, carry genetic information from the placenta. Preeclampsia, linked to abnormal placental development and function, is associated with the release of altered cfDNA.

Quantitative analysis of cfDNA levels has emerged as a promising approach for assessing preeclampsia. Studies have demonstrated elevated levels of cfDNA in the maternal circulation during pregnancies complicated by preeclampsia compared to normal pregnancies. This quantitative assessment may serve as an indicative measure for the presence and severity of preeclampsia.

Moreover, researchers are delving into the genomic and epigenomic changes within cfDNA to pinpoint specific genetic or epigenetic alterations associated with preeclampsia. Aberrations in DNA sequence or methylation patterns could offer valuable insights for early detection and risk assessment.

The diagnostic potential of cfDNA is particularly significant. Being non-invasive, cfDNA holds promise as an early diagnostic biomarker for preeclampsia. Timely detection is crucial for implementing interventions and management strategies to mitigate the risk of complications for both the mother and the baby.

Continuous monitoring of cfDNA levels throughout pregnancy presents an avenue for tracking the progression of preeclampsia. Changes in cfDNA concentrations over time could inform healthcare providers, enabling them to adjust management strategies as needed.

While these findings offer promising prospects, it’s essential to note that the use of cfDNA as a biomarker for pre-eclampsia is still in the investigative stage. Further validation and standardization of testing methods are necessary before cfDNA testing becomes a routine component of prenatal care.

Pregnant individuals at high risk for pre-eclampsia may benefit from closer monitoring, and ongoing research aims to refine the practical application of cfDNA in clinical practice. As developments unfold, consulting with healthcare professionals remains crucial for obtaining the most up-to-date information on prenatal screening and diagnostic tools.